Michelle M Mielke1. 1. Departments of Health Sciences Research and Neurology, Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: The development of cerebrospinal fluid and blood-based biomarkers for Alzheimer disease (AD) and related disorders is rapidly progressing. Such biomarkers may be used clinically to screen the population, to enhance diagnosis, or to help determine prognosis. Although the use of precision medicine methods has contributed to enhanced understanding of the AD pathophysiological changes and development of assays, one aspect not commonly considered is sex differences. CONTENT: There are several ways in which sex can affect the concentration or interpretation of biofluid biomarkers. For some markers, concentrations will vary by sex. For others, the concentrations might not vary by sex, but the impact or interpretation may vary by sex depending on the context of use (e.g., diagnostic vs prognostic). Finally, for others, there will be no sex differences in concentrations or their interpretation. This review will first provide a basis for sex differences, including differences in brain structure and function, and the means by which these differences could contribute to sex differences in biomarker concentrations. Next, the current state of sex differences in AD-related biofluid markers (i.e., amyloid-β, phosphorylated τ, total τ, neurofilament light chain, and neurogranin) will be reviewed. Lastly, factors that can lead to the misinterpretation of observed sex differences in biomarkers (either providing evidence for or against) will be considered. SUMMARY: This review is intended to provide an impetus to consider sex differences in the measurement and interpretation of AD-related biofluid-based biomarkers.
BACKGROUND: The development of cerebrospinal fluid and blood-based biomarkers for Alzheimer disease (AD) and related disorders is rapidly progressing. Such biomarkers may be used clinically to screen the population, to enhance diagnosis, or to help determine prognosis. Although the use of precision medicine methods has contributed to enhanced understanding of the AD pathophysiological changes and development of assays, one aspect not commonly considered is sex differences. CONTENT: There are several ways in which sex can affect the concentration or interpretation of biofluid biomarkers. For some markers, concentrations will vary by sex. For others, the concentrations might not vary by sex, but the impact or interpretation may vary by sex depending on the context of use (e.g., diagnostic vs prognostic). Finally, for others, there will be no sex differences in concentrations or their interpretation. This review will first provide a basis for sex differences, including differences in brain structure and function, and the means by which these differences could contribute to sex differences in biomarker concentrations. Next, the current state of sex differences in AD-related biofluid markers (i.e., amyloid-β, phosphorylated τ, total τ, neurofilament light chain, and neurogranin) will be reviewed. Lastly, factors that can lead to the misinterpretation of observed sex differences in biomarkers (either providing evidence for or against) will be considered. SUMMARY: This review is intended to provide an impetus to consider sex differences in the measurement and interpretation of AD-related biofluid-based biomarkers.
Authors: Gil D Rabinovici; Constantine Gatsonis; Charles Apgar; Kiran Chaudhary; Ilana Gareen; Lucy Hanna; James Hendrix; Bruce E Hillner; Cynthia Olson; Orit H Lesman-Segev; Justin Romanoff; Barry A Siegel; Rachel A Whitmer; Maria C Carrillo Journal: JAMA Date: 2019-04-02 Impact factor: 56.272
Authors: Silke Kern; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Ingmar Skoog; Margda Waern; Clinton E Hagen; Argonde C van Harten; David S Knopman; Clifford R Jack; Ronald C Petersen; Michelle M Mielke Journal: JAMA Neurol Date: 2019-02-01 Impact factor: 18.302
Authors: R C Gur; P D Mozley; S M Resnick; G L Gottlieb; M Kohn; R Zimmerman; G Herman; S Atlas; R Grossman; D Berretta Journal: Proc Natl Acad Sci U S A Date: 1991-04-01 Impact factor: 11.205
Authors: Y M Kuo; T A Kokjohn; W Kalback; D Luehrs; D R Galasko; N Chevallier; E H Koo; M R Emmerling; A E Roher Journal: Biochem Biophys Res Commun Date: 2000-02-24 Impact factor: 3.575
Authors: Claire Bridel; Wessel N van Wieringen; Henrik Zetterberg; Betty M Tijms; Charlotte E Teunissen; José C Alvarez-Cermeño; Ulf Andreasson; Markus Axelsson; David C Bäckström; Ales Bartos; Maria Bjerke; Kaj Blennow; Adam Boxer; Lou Brundin; Joachim Burman; Tove Christensen; Lenká Fialová; Lars Forsgren; Jette L Frederiksen; Magnus Gisslén; Elizabeth Gray; Martin Gunnarsson; Sara Hall; Oskar Hansson; Megan K Herbert; Joel Jakobsson; Jan Jessen-Krut; Shorena Janelidze; Gudmundur Johannsson; Michael Jonsson; Ludwig Kappos; Mohsen Khademi; Michael Khalil; Jens Kuhle; Mikael Landén; Ville Leinonen; Giancarlo Logroscino; Ching-Hua Lu; Jan Lycke; Nadia K Magdalinou; Andrea Malaspina; Niklas Mattsson; Lieke H Meeter; Sanjay R Mehta; Signe Modvig; Tomas Olsson; Ross W Paterson; Josué Pérez-Santiago; Fredrik Piehl; Yolande A L Pijnenburg; Okko T Pyykkö; Oskar Ragnarsson; Julio C Rojas; Jeppe Romme Christensen; Linda Sandberg; Carole S Scherling; Jonathan M Schott; Finn T Sellebjerg; Isabella L Simone; Tobias Skillbäck; Morten Stilund; Peter Sundström; Anders Svenningsson; Rosanna Tortelli; Carla Tortorella; Alessandro Trentini; Maria Troiano; Martin R Turner; John C van Swieten; Mattias Vågberg; Marcel M Verbeek; Luisa M Villar; Pieter Jelle Visser; Anders Wallin; Andreas Weiss; Carsten Wikkelsø; Edward J Wild Journal: JAMA Neurol Date: 2019-09-01 Impact factor: 18.302
Authors: Lauren M Byrne; Filipe B Rodrigues; Eileanoir B Johnson; Enrico De Vita; Kaj Blennow; Rachael Scahill; Henrik Zetterberg; Amanda Heslegrave; Edward J Wild Journal: Sci Rep Date: 2018-03-09 Impact factor: 4.379
Authors: Amaryllis A Tsiknia; Steven D Edland; Erin E Sundermann; Emilie T Reas; James B Brewer; Douglas Galasko; Sarah J Banks Journal: Mol Psychiatry Date: 2022-06-29 Impact factor: 15.992
Authors: Michelle M Mielke; Neelum T Aggarwal; Clara Vila-Castelar; Puja Agarwal; Eider M Arenaza-Urquijo; Benjamin Brett; Anna Brugulat-Serrat; Lyndsey E DuBose; Willem S Eikelboom; Jason Flatt; Nancy S Foldi; Sanne Franzen; Paola Gilsanz; Wei Li; Alison J McManus; Debora Melo van Lent; Sadaf Arefi Milani; C Elizabeth Shaaban; Shana D Stites; Erin Sundermann; Vidyani Suryadevara; Jean-Francoise Trani; Arlener D Turner; Jet M J Vonk; Yakeel T Quiroz; Ganesh M Babulal Journal: Alzheimers Dement Date: 2022-04-08 Impact factor: 16.655
Authors: Jeremy A Syrjanen; Michelle R Campbell; Alicia Algeciras-Schimnich; Prashanthi Vemuri; Jonathan Graff-Radford; Mary M Machulda; Guojun Bu; David S Knopman; Clifford R Jack; Ronald C Petersen; Michelle M Mielke Journal: Alzheimers Dement Date: 2021-09-27 Impact factor: 16.655
Authors: Christoph Kessler; Lina M Serna-Higuita; Tim W Rattay; Walter Maetzler; Isabel Wurster; Stefanie Hayer; Carlo Wilke; Holger Hengel; Jennifer Reichbauer; Marcel Armbruster; Ludger Schöls; Peter Martus; Rebecca Schüle Journal: Ann Clin Transl Neurol Date: 2021-04-05 Impact factor: 4.511
Authors: Christoph Kessler; Lina Maria Serna-Higuita; Carlo Wilke; Tim W Rattay; Holger Hengel; Jennifer Reichbauer; Elke Stransky; Alejandra Leyva-Gutiérrez; David Mengel; Matthis Synofzik; Ludger Schöls; Peter Martus; Rebecca Schüle Journal: Ann Clin Transl Neurol Date: 2022-02-16 Impact factor: 4.511
Authors: Emma L Robertson; Susan E Boehnke; Natalia de M Lyra E Silva; Brittney Armitage-Brown; Andrew Winterborn; Douglas J Cook; Fernanda G De Felice; Douglas P Munoz Journal: Alzheimers Dement (N Y) Date: 2022-04-05
Authors: Carmen Freire-Cobo; Melissa K Edler; Merina Varghese; Emily Munger; Jessie Laffey; Sophia Raia; Selena S In; Bridget Wicinski; Maria Medalla; Sylvia E Perez; Elliott J Mufson; Joseph M Erwin; Elaine E Guevara; Chet C Sherwood; Jennifer I Luebke; Agnès Lacreuse; Mary A Raghanti; Patrick R Hof Journal: Am J Primatol Date: 2021-07-13 Impact factor: 2.371